project id: TCGA-BLCA; case submitter id: TCGA-BT-A42C; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.81; rna integrity number: 8.9; age at index: 64; days to birth: -23584; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 23584; ajcc clinical t: T2a; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 873.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8130/3; primary diagnosis: Papillary transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 7.232876712328767; pack years smoked: 132.0; is ffpe: false; composition: Not Reported; days to collection: 274; days to sample procurement: 0; initial weight: 190.0; portion submitter id: TCGA-BT-A42C-01A-11; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 28.0; percent tumor cells: 70.0; percent tumor nuclei: 92.0;